West Pharmaceutical Services, Inc. WST

370.44 (3.16) (0.85%) as of 25 Sep
Market cap
$26.3B
P/E
47.1×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

West Pharmaceutical Services, Inc. (WST) Revenue growth

West Pharmaceutical Services, Inc.'s revenue growth over the twelve months to 30 June 2026 was 12.4%, up 6.1 percentage points from fiscal 2025 (6.25%). Over the past ten years it has ranged from −1.92% (fiscal 2024) to 31.9% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Medical Instruments & Supplies industry median of 9.20% and above the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 6.25% 8.17
FY2024 −1.92% (4.10)
FY2023 2.18% 0.23
FY2022 1.95% (29.94)
FY2021 31.9% 15.20
FY2020 16.7% 9.56
FY2019 7.13% (0.27)
FY2018 7.40% 1.44
FY2017 5.96% (1.85)
FY2016 7.81% 9.33

Quarterly

Period Revenue growth Change (points)
Jun 2026 13.8% (7.25)
Mar 2026 21.1% 13.54
Dec 2025 7.51% (0.22)
Sep 2025 7.73% (1.44)
42 more quarters

Against its own ten years

Low −1.92% High 31.9%
Ten-year median 6.25%
Current reading's percentile 55

Revenue growth against peers

Company Revenue growth
RGEN Repligen Corporation compare 16.5%
BDX Becton, Dickinson and Company compare 13.1%
WST West Pharmaceutical Services, Inc. 12.4%
RMD ResMed Inc. compare 9.85%
ALC Alcon compare 8.34%
BAX Baxter International Inc. compare 5.36%
COO The Cooper Companies, Inc. compare 4.73%
SOLV Solventum Corporation compare −0.93%
MDLN Medline Inc. compare —
Medical Instruments & Supplies industry median 9.20%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on WST